Kardio-Med Silesia – Śląski Park Technologii Medycznych

Publikacje

Titanium dioxide nanoparticles enhance production of superoxide anion and alter the antioxidant system in human osteoblast cells, International Journal of Nanomedicine 2015, vol. 10, p. 1095-1107.
Autorzy: Niska K., Pyszka K., Tukaj C., Wozniak C, Radomski M. W., Inkielewicz-Stepniak I.

CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: Protective effect of crocetin, Toxicol. Vitro 2015, vol. 29, p. 663-671.
Autorzy: Niska K.,Santos Martinez M.J.,Radomski M.,Inkielewicz- Stepniak I.

Nanodiagnostics, nanopharmacology and nanotoxicology of platelet – vessel wall interactions, Nanomedicine (Lond.), vol. 10, p.1451-1475.
Autorzy: Tomaszewski K. A., Santos-Martinez M. J., Radomski M. W.

Pharmacological characterization of nanoparticle – induced pratelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry”, International Journal of Nanomedicine 2015, vol. 10, p. 5107-5119.
Autorzy: Santos-Martinez M. J., Tomaszewski K. A., Medina C., Bazou D., Gilmer . J., Radomski M. W.

Magnetic Nanopartitles in Cancer Theranostics, Theranostics 2015, vol. 5, Issue 11, p. 1249-1263.
Autorzy: Gobbo O. L., Sjaastad K., Radomski M. W., Volkov Y., Prina-Mello A.

Nanopharmacology and nanotoxicology of nanomaterials: new opportunites and challenges, Advances in Clinical and Experimental Medicine 2016, vol. 1, p. 151-162.
Autorzy: Radomska A., Leszczyszyn J., Radomski M. W.,

The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent, Plos One 2016, vol. 3, e. 0150500.
Autorzy: Osadnik T., Strzelczyk J. K., Reguła R., Bujak K., Fronczek M., Gonera M., Gawlita M., Wasilewski J., Lekston A., Kurek A., Gierlotka M., Trzeciak P., Hawranek M., Ostrowska Z., Wiczkowski A., Poloński L., Gąsior M.

Functional polymorphism rs710218 in the gene coding GLUT1 protein is associated with in-stent restenosis, Biomarkers in Medicine 2015, vol. 9, p. 743-50.
Autorzy: Osadnik T., Strzelczyk J., Bujak K., Reguła R., Wasilewski J., Fronczek M., Kurek A., Gawlita M., Gonera M., Gierlotka M., Lekston A., Hawranek M., Myrda K., Wiczkowski A., Ostrowska Z., Gąsior M., Poloński L.

The prognostic role of red blood cell distribution width in coronary artery disease: A review of the pathophysiology, Disease markers 2015, vol. 1, p. 1-12.
Autorzy: Bujak K., Wasilewski J., Osadnik T., Jonczyk S., Kołodziejska A., Gierlotka M., Gąsior M.,

Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center, Trials 2015, vol. 16, p. 400-411.
Autorzy: Wasilewski J., Poloński L., Lekston A., Osadnik T., Reguła R., Bujak K., Kurek A.

Prognostic implications of mean platelet volume on short- and long-term outcomes among patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: A single-center large observational study, A single-center large observational study, Platelets 2016, vol. 5, p. 452-458.
Autorzy: Wasilewski J., Desperak P., Hawranek M., Ciślak A., Osadnik T., Pyka Ł., Gawlita M., Bujak K., Niedziela J., Krawczyk M., Gąsior M.

Prognostic value of neutrophil – to – lymphocyte ratio in predicting long – term mortality in patients with ischemic and nonischemic heart failure, Polish Archives of Internal Medicine 2016, vol. 3, p. 166-173.
Autorzy: Wasilewski J., Pyka Ł., Hawranek M., Osadnik T., Kurek A., Skrzypek M., Niedziela J., Desperak P., Kułaczkowska Z., Brzezina M., Krawczyk M., Gąsior M.

Relationship of the rs1799752 polymorphism 4 of the angiotensin-converting enzyme gene and the rs699 5 polymorphism of the angiotensinogen gene to the process of in-stent 6 restenosis in a population of Polish patients with stable coronary 7 artery disease, Advances in Medical Sciences 2016, vol. 2, p. 276-281.
Autorzy: Osadnik T., Strzelczyk J. K., Fronczek M., Bujak K., Reguła R., Gonera M., Gawlita M., Kurek A., Wasilewski J., Lekston A., Gierlotka M., Hawranek M., Ostrowska Z., Wiczkowski A., Poloński L., Gąsior M.

Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population, Heart Rhythm 2016
Autorzy: Sokal A., Lenarczyk R., Kowalski O., Mitręga K., Pluta S., Stabryła- Deska J., Streb W., Urbanik Z., Krzemiński TF., Kalarus Z.

Molecular Mechanism of Silver Nanoparticles-InducedHuman Osteoblast Cell Death: Protective Effect of Inducible Nitric Oxide Synthase Inhibitor, Plos One 2016, vol. 10, e: 0164137.
Autorzy: Zielinska E., Tukaj C., Radomski M. W., Inkielewicz-Stepniak I.

The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease, BMC Cardiovascular Disorders 2016
Autorzy: Osadnik T., Strzelczyk J., Lekston A., Reguła R., Bujak K., Fronczek M., Gawlita M., Gonera M., Wasilewski J., Szyguła- Jurkiewicz B., Gierlotka M., Gąsior M.

Pol-Tavi – Polish Registry of Transcatheter aortic valve implantation – simple tool, great value, rationale and design, Kardiochirurgia i Torakochirurgia Polska 2016, vol. 13, p. 309-315
Autorzy: Zembala- John J., Wilczek K.,Tobota Z., Chodór P., Cieśla D., Jaźwiec T., Banasiak W., Stępińska J., Kalarus Z., Opolski G., Zembala M.

Valproic acid downregulates heme oxygenase-1 independently of Nrf2 by increasing ubiquitination and proteasomal degradation, Biochemical and Biophysical Research Communications 2017
Autorzy: Jez M, Ciesla M, Stepniewski J, Langrzyk A, Muchova L, Vitek L, Jozkowicz A, Dulak J.



Please leave this field empty.

Wyrażam zgodę na przetwarzanie moich danych osobowych zawartych w powyższym formularzu kontaktowym, przez Kardio-Med Silesia Sp. z o. o. z siedzibą w Zabrzu (ul. M. Curie- Skłodowskiej 10C, 41-800 Zabrze) zgodnie z Ustawą z dnia 29.08.97r. o Ochronie Danych Osobowych, w celu uzyskania odpowiedzi na zapytanie.